Associated Genetic Biomarkers
SLFN11 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains SLFN11 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with SLFN11 status in the inclusion eligibility criteria most commonly target small cell lung carcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is SLFN11 Expression .
Atezolizumab and talazoparib are the most frequent therapies in trials with SLFN11 as an inclusion criteria .
Significance of SLFN11 in Diseases
Small Cell Lung Carcinoma +
SLFN11 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLFN11 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.